Clinical Trials Logo

Spasms, Infantile clinical trials

View clinical trials related to Spasms, Infantile.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03976076 Terminated - Clinical trials for Refractory Infantile Spasms

A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients

Start date: April 15, 2020
Phase: Phase 2
Study type: Interventional

A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients.

NCT ID: NCT03421496 Terminated - Infantile Spasm Clinical Trials

A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms

Start date: September 5, 2018
Phase: Phase 3
Study type: Interventional

The primary purpose of this study was to evaluate the efficacy, safety, and tolerability of Cannabidiol Oral Solution (CBD) as adjunctive therapy with vigabatrin as initial therapy, compared to vigabatrin alone in the treatment of infants newly diagnosed with Infantile Spasms (IS).

NCT ID: NCT02829827 Terminated - Clinical trials for Infantile Spasms (IS)

A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)

Start date: December 4, 2017
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety and tolerability, the pharmacokinetics and the efficacy of radiprodil in abolishing clinical spasms in subjects with drug-resistant infantile spasms

NCT ID: NCT02551731 Terminated - Spasms, Infantile Clinical Trials

Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms

Start date: January 27, 2016
Phase: Phase 2
Study type: Interventional

Infantile Spasms (IS) is a diagnosis described as a fairly rare and terrible form of epilepsy that usually strikes children in the first year of life. There is a great need for safe and effective therapies in the treatment of IS. This need is even more important for infants and toddlers still sick after being treated with medicine that is already available. This is a multi-center study to evaluate the efficacy and safety of Cannabidiol Oral Solution (CBD) in the treatment of children aged 6 months through 36 months with a diagnosis of infantile spasms who have not responded to first line therapies. The overall study duration is expected to be 64 weeks for those subjects who respond to CBD treatment. The maximum possible study duration for each patient is approximately 64 weeks, however a subject will be deemed to have completed the study after 58 weeks.

NCT ID: NCT00442104 Terminated - Infantile Spasms Clinical Trials

Open-label Extension to Protocol 1042-0500

Start date: January 2007
Phase: Phase 2
Study type: Interventional

To allow open-label extension to patients who have completed Protocol 1042-0500